H.C. Wainwright Reiterates Their Buy Rating on Rockwell Med (RMTI)

By Carrie Williams

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med (RMTIResearch Report), with a price target of $11.00. The company’s shares closed last Monday at $2.60, close to its 52-week low of $1.81.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 13.0% and a 51.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.

Currently, the analyst consensus on Rockwell Med is a Moderate Buy with an average price target of $8.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.88 and a one-year low of $1.81. Currently, Rockwell Med has an average volume of 371.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rockwell Medical, Inc. engages in targeting end-stage renal disease and chronic kidney disease. Its dialysis products include hemodialysis concentrates, citrapure, dri-sate, safety data sheets,ancillary products, and renal pure. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.